Hospital
Wellmont Health System
Wellmont Health System was paid $17.64M by Medicaid between Jan 2018 and Dec 2024, across 160 billing codes. Its largest line is 99284, emergency room visit (serious) — 40% of everything it billed.
33Billing provider infoWELLMONT HEALTH SYSTEM
KINGSPORT, TN 37660
KINGSPORT, TN 37660
33aNPI1487690400assigned 06/20/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$17.64M
24GClaims422,589
24DCodes billed160
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Tennessee
Rank by total paid#14 of 71
Median peer was paid$6.96M
This provider vs. median2.5×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official HILTON, SHANE controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 79,345 | $2.82M | |
| 2019 | 79,580 | $2.61M | |
| 2020 | 56,909 | $2.73M | |
| 2021 | 57,929 | $2.63M | |
| 2022 | 50,555 | $2.27M | |
| 2023 | 59,916 | $2.65M | |
| 2024incomplete | 38,355 | $1.93M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 40% | 35,151 | 30,280 | $7.05M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 20% | 16,145 | 13,466 | $3.53M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 14% | 17,946 | 15,974 | $2.42M |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 2.7% | 1,847 | 1,647 | $473K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | 2.0% | 818 | 708 | $360K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.0% | 4,985 | 4,576 | $358K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.0% | 2,227 | 1,957 | $355K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.7% | 1,552 | 1,211 | $305K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.7% | 2,690 | 2,240 | $302K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 1.1% | 3,152 | 2,768 | $194K |
| G0378 | Hospital observation service, per hour | <1% | 3,332 | 1,884 | $145K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 10,046 | 8,453 | $142K |
148 more codes
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 47,200 | $114K |
| 93017 | <1% | 1,226 | $111K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 1,552 | $105K |
| 80053 | Comprehensive metabolic panel | <1% | 38,234 | $98K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 603 | $91K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 4,221 | $79K |
| C8929 | Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, complete, with spectral doppler echocardiography, and with color flow doppler echocardiography | <1% | 365 | $78K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 8,994 | $78K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 305 | $70K |
| 93922 | <1% | 1,091 | $69K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 400 | $67K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 1,963 | $63K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 1,473 | $59K |
| 84484 | <1% | 13,154 | $58K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 19,800 | $54K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,131 | $47K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 516 | $46K |
| 93880 | <1% | 591 | $38K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 578 | $37K |
| 36415 | Collection of venous blood by venipuncture | <1% | 32,884 | $34K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 729 | $33K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 588 | $33K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 6,678 | $30K |
| 77412 | <1% | 906 | $30K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 7,302 | $27K |
| 76641 | <1% | 204 | $24K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 832 | $24K |
| 95886 | <1% | 612 | $24K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 394 | $20K |
| 71045 | Radiologic examination, chest; single view | <1% | 4,825 | $19K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 42 | $19K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 73 | $18K |
| 77336 | <1% | 586 | $15K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 83 | $14K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 562 | $13K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 3,627 | $13K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 4,927 | $12K |
| C1776 | Joint device (implantable) | <1% | 60 | $12K |
| 83880 | <1% | 2,666 | $12K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 5,053 | $11K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 311 | $11K |
| 83690 | <1% | 6,057 | $10K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 201 | $10K |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 223 | $9K |
| 81001 | <1% | 14,162 | $9K | |
| 97162 | <1% | 210 | $9K | |
| 93971 | <1% | 97 | $8K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 82 | $8K |
| 72141 | <1% | 46 | $7K | |
| 77014 | <1% | 267 | $7K | |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 1,645 | $7K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 34 | $7K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 164 | $7K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 6,681 | $7K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 1,005 | $6K |
| 77334 | <1% | 103 | $6K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 2,619 | $6K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 549 | $6K |
| 81025 | <1% | 4,114 | $6K | |
| 77300 | <1% | 148 | $5K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 53 | $4K |
| 81003 | <1% | 6,171 | $4K | |
| Q9950 | Injection, sulfur hexafluoride lipid microspheres, per ml | <1% | 883 | $3K |
| 73221 | <1% | 27 | $3K | |
| 62323 | <1% | 12 | $3K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 233 | $3K |
| 87040 | <1% | 349 | $3K | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 75 | $3K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 153 | $3K |
| 85027 | <1% | 1,771 | $3K | |
| 86901 | <1% | 1,079 | $2K | |
| 85610 | <1% | 2,029 | $2K | |
| 95911 | <1% | 33 | $2K | |
| 86850 | <1% | 929 | $2K | |
| 87641 | <1% | 149 | $2K | |
| 96376 | <1% | 1,018 | $2K | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 129 | $2K |
| 72100 | <1% | 119 | $2K | |
| 94760 | <1% | 959 | $2K | |
| 71250 | <1% | 35 | $1K | |
| 87640 | <1% | 103 | $1K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 2,566 | $1K |
| 88342 | <1% | 154 | $1K | |
| 82565 | <1% | 817 | $1K | |
| 95909 | <1% | 28 | $1K | |
| 83735 | <1% | 1,715 | $980.42 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 4,014 | $967.03 |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 546 | $947.79 |
| 86900 | <1% | 1,035 | $876.23 | |
| 83605 | <1% | 364 | $826.53 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 268 | $752.90 |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 661 | $727.32 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 3,249 | $715.94 |
| 77066 | Tomosynthesis, mammo | <1% | 13 | $665.94 |
| 99153 | Mod sedat endo service >5yrs | <1% | 355 | $565.23 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 5,439 | $517.14 |
| 95912 | <1% | 12 | $469.74 | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 137 | $459.02 |
| 87081 | <1% | 213 | $386.55 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 2,241 | $379.54 |
| 99152 | <1% | 679 | $349.92 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 2,861 | $321.77 |
| 80143 | <1% | 104 | $304.80 | |
| 85730 | <1% | 314 | $281.41 | |
| 80179 | <1% | 107 | $240.71 | |
| 97116 | <1% | 25 | $175.21 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 2,936 | $172.45 |
| Q9957 | Injection, perflutren lipid microspheres, per ml | <1% | 16 | $165.71 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,355 | $164.69 |
| 84100 | <1% | 511 | $161.94 | |
| 80061 | Lipid panel | <1% | 35 | $147.69 |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 834 | $137.15 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 536 | $129.23 |
| 85379 | <1% | 30 | $118.75 | |
| 73562 | <1% | 27 | $118.60 | |
| 74018 | <1% | 29 | $106.81 | |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 467 | $80.68 |
| J3490 | Unclassified drugs | <1% | 1,295 | $74.19 |
| 76000 | <1% | 14 | $53.83 | |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 905 | $46.56 |
| C1769 | Guide wire | <1% | 272 | $40.52 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 472 | $38.06 |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 12 | $35.09 |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 575 | $25.89 |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 254 | $24.58 |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 245 | $23.93 |
| 85652 | <1% | 49 | $17.04 | |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 248 | $13.05 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 107 | $8.51 |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 92 | $6.54 |
| J2704 | Injection, propofol, 10 mg | <1% | 2,205 | $6.16 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 87 | $6.08 |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 54 | $5.50 |
| 87186 | <1% | 32 | $3.87 | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 328 | $3.75 |
| A9270 | Non-covered item or service | <1% | 7,786 | $2.00 |
| 84703 | <1% | 12 | $1.93 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 33 | $1.32 |
| 29581 | 0% | 53 | $0.00 | |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | 0% | 166 | $0.00 |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | 0% | 83 | $0.00 |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | 0% | 14 | $0.00 |
| 87077 | 0% | 13 | $0.00 | |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | 0% | 390 | $0.00 |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | 0% | 54 | $0.00 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 20 | $0.00 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 20 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 58 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialHILTON, SHANE (EVP/CFO)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.